The Effect of Ulipristal Acetate (UPA) on Women Ovarian Reserve
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The uterine leiomyoma is the most common female benign disease.UPA seems to be most effective
for the medical management of fibroids and could be place as preoperative adjunct to surgery
but also as medical therapy to avoid surgery. No data have been published about the effect of
UPA on FSH (Follicle stimulating hormone) or AMH levels nor on ovarian antral follicle count
(AFC) or vascularization indexes during and after treatment. Considering that in young women
of reproductive age (under 40 years old), desiring pregnancy, UPA has been proposed to avoid
or postpone surgery, also in a long-term administration program, data about its effect on
women ovarian reserve are urgently needed.
For these reasons, data on biochemical (AMH, FSH and E2) and 3D ultrasonographic (VI, Flow
index, AFC) parameters of women treated by UP are needed to assess the effect of the drug in
terms of ovarian reserve modification.